Why Achillion Pharmaceuticals Inc. Shares Soared

Achillion rides the coattails of a rival to the upside. Find out what investors should be keeping their eyes on following Achillion's big move.

Jun 9, 2014 at 2:41PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Achillion Pharmaceuticals (NASDAQ:ACHN), a clinical-stage biopharmaceutical company focused on researching therapies to treat hepatitis C, climbed as much as 44% on speculation that it could be a buyout target.

So what: The primary impetus for Achillion's spike is Merck's (NYSE:MRK) $3.85 billion purchase of Idenix Pharmaceuticals (NASDAQ:IDIX), which was announced before the opening bell today. According to CNBC reporter David Faber, the 239% premium paid for Idenix resulted from a bidding war between Merck, Johnson & Johnson, and surprisingly AbbVie, which has its own direct-acting antiviral combo drug under review by the Food and Drug Administration. The thought here is that J&J, AbbVie, or some other suitor could be interested in Achillion's pipeline considering its focus on hepatitis C. The Centers for Disease Control and Prevention says more than 3 million people in the U.S. have hepatitis C (although most people are unaware they have the disease), with some 180 million people worldwide carrying the disease, per the World Health Organization.

Now what: The rumor mill is certainly working overtime today considering what I believe to be the insane price Merck paid to acquire a company that had four investigational therapies placed on clinical hold over the past four years.

Achillion is, unfortunately, in a somewhat similar boat. Although it has four investigational products in trials, its lead drug, sovaprevir, has been on clinical hold since last summer after investigators found elevated ALT liver enzyme levels in patients following a phase 1 study. Its future is as cloudy as ever with management expecting the clinical hold to have been lifted last year. Even with additional phase 1 and 2 studies under way, what value is there if Achillion, like Idenix, can't get any of its therapies safely past midstage studies? In addition, with hepatitis C patients already welcoming Gilead Sciences' Sovaldi with open arms, and maybe AbbVie's direct-acting antiviral combo later this year, what market share would Achillion be looking at when its drugs hit pharmacy shelves in two or three years? I would suggest investors ignore their urge to trade on emotion and stick to the sidelines here.

Achillion shares may have soared today, but it'll likely have a tough time keeping pace with this top stock over the long run
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers